Cabaletta Bio, Inc. (CABA)
Nasdaq · Healthcare · Biotechnology
$2.08+4.00%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $353M
- 52-week range
- $1.83 – $4.23
- 52-week change
- −13.79%
- EPS (trailing)
- −$1.51
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Net income
- −$168M
- Diluted EPS
- −$2.10
- Free cash flow
- −$132M
From the company’s annual report on SEC EDGAR.
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc.
Headquarters: Philadelphia, United States · 154 employees · cabalettabio.com